Equities

SymBio Pharmaceuticals Ltd

SymBio Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)252.00
  • Today's Change4.00 / 1.61%
  • Shares traded776.70k
  • 1 Year change-32.44%
  • Beta0.7583
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
REVENUE AND GROSS PROFIT
Total revenue5,59010,0088,257
OPERATING EXPENSES
Cost of revenue total1,1792,4082,457
Selling, general and admin. expenses, total2,5843,0092,979
Depreciation/amortization--7269
Unusual expense(income)492(106)(0.2)
Other operating expenses, total0.000.000.00
Total operating expense6,8947,9387,241
Operating income(1304)2,0701,016
Other, net(20)(100)2.68
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes(1195)2,1061,001
Provision for income taxes767927(1031)
Net income after taxes(1963)1,1792,032
Minority interest------
Net income before extra. Items(1963)1,1792,032
Total extraordinary items------
Net income(1963)1,1792,032
Inc.avail. to common excl. extra. Items(1963)1,1792,032
Inc.avail. to common incl. extra. Items(1963)1,1792,032
EPS RECONCILIATION
Basic/primary weighted average shares403938
Basic/primary eps excl. extra items(49)3053
Basic/primary eps incl. extra items(49)3053
Dilution adjustment------
Diluted weighted average shares404039
Diluted eps excl. extra items(49)3052
Diluted eps incl. extra items(49)3052
COMMON STOCK DIVIDENDS
DPS - common stock primary issue000
Gross dividend - common stock000
PRO FORMA INCOME
Pro forma net income------
Interest expense, supplemental------
SUPPLEMENTAL INCOME
Depreciation, supplemental969814
Total special items492(106)(0.2)
NORMALISED INCOME
Normalized income before taxes(703)2,0001,001
Effect of special items on income taxes172(47)(0.07)
Income tax excluding impact of special items940880(1031)
Normalized income after tax(1643)1,1202,032
Normalized income avail. to common(1643)1,1202,032
Basic normalized EPS(41)2953
Diluted normalized EPS(41)2852
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.